Global Point-of-Care (POC) Infectious Disease Diagnostics Market Growth, Share, Size, Trends and Forecast (2025 - 2031)

This report extensively covers different segments of Global Point-of-Care (POC) Infectious Disease Diagnostics Market and provides an in depth analysis (including revenue analysis for both historic and forecast periods) for all the market segments. In this report, the analysis for every market segment is substantiated with relevant data points and, insights that are generated from analysis of these data points (data trends and patterns).

Global Point-of-Care (POC) Infectious Disease Diagnostics Segment Analysis

In this report, the Global Point-of-Care (POC) Infectious Disease Diagnostics Market has been segmented by Technology, Application, End User and Geography.

Global Point-of-Care (POC) Infectious Disease Diagnostics Market, Segmentation by Technology

The Global Point-of-Care (POC) Infectious Disease Diagnostics Market has been segmented by Technology into Lateral Flow, Agglutination Assays, Flow-Through and Solid Phase.

The global point-of-care infectious disease diagnostics market is segmented by technology, with key categories including lateral flow, agglutination assays, flow-through, and solid phase. Each technology plays a unique role in enabling rapid and reliable diagnostic results, which are critical in managing infectious diseases effectively. Lateral flow assays, for instance, are among the most widely used technologies within this market. Their popularity is largely due to their ease of use, quick turnaround time, and cost-effectiveness, making them ideal for use in various healthcare settings, including remote or resource-limited areas. These assays typically work by allowing a sample to pass through a membrane, where specific antibodies react with the target pathogen, leading to visible results.

Agglutination assays, another prominent technology in the POC diagnostics segment, operate through antigen-antibody interactions that cause particles in the sample to clump or agglutinate, indicating the presence of a specific infectious agent. This technology is particularly valuable in detecting certain bacterial and viral infections and is often employed due to its simplicity and effectiveness. Although agglutination assays may not always be as rapid as lateral flow assays, they offer reliable specificity and sensitivity for a range of infectious agents. Additionally, the method’s adaptability to diverse pathogens makes it a versatile tool in POC diagnostics, particularly in point-of-care settings where rapid decision-making is essential.

Flow-through and solid-phase assays complete the technological segmentation of the market, each bringing unique strengths to the field. Flow-through assays are valued for their fast processing time and high sensitivity, achieved by allowing the sample to flow through a membrane and react with immobilized antibodies specific to the target pathogen. This technology is particularly useful in screening for infections with higher sensitivity demands. Solid-phase assays, on the other hand, involve a fixed surface on which antigen-antibody reactions occur, enhancing assay stability and accuracy. This technology is often utilized for tests that require precise, stable results over a longer period, which is essential for specific diagnostic needs in infectious diseases. Both flow-through and solid-phase assays thus broaden the scope and application of POC diagnostics in managing infectious disease outbreaks, further contributing to the market’s growth potential.

Global Point-of-Care (POC) Infectious Disease Diagnostics Market, Segmentation by Application

The Global Point-of-Care (POC) Infectious Disease Diagnostics Market has been segmented by Application into HIV, Tropical Disease, Liver Disease, Inflammatory Disease, Respiratory Disease, Hospital Associated Infections (HAIs), Sexual Health Disorders and Others.

The Global Point-of-Care (POC) Infectious Disease Diagnostics Market is categorized by application, addressing various infectious diseases and conditions for quick, on-the-spot diagnosis. One of the prominent segments is HIV, as point-of-care diagnostics play a vital role in identifying and managing HIV cases, especially in regions with limited healthcare access. These rapid diagnostics help reduce the spread of HIV by providing timely detection and enabling prompt treatment. Moreover, POC diagnostics in this segment are beneficial for large-scale screening programs, community testing initiatives, and for reducing stigma through faster, more private testing options.

Another important application segment includes tropical diseases, which covers infectious diseases prevalent in warmer climates, such as malaria, dengue, and Zika virus. POC diagnostics are instrumental in these areas because they allow healthcare providers to detect and treat these diseases early, helping to curb potential outbreaks. Tropical diseases often have a high mortality rate when untreated, making rapid diagnosis a critical component in mitigating disease impact and guiding timely treatment in remote or resource-limited settings. Additionally, portable POC diagnostic tools are well-suited to fieldwork and mobile clinics in rural and underserved regions, where tropical diseases are most common.

In addition to HIV and tropical diseases, the POC infectious disease diagnostics market encompasses other applications like liver diseases, respiratory diseases, hospital-associated infections, sexual health disorders, and inflammatory diseases. Each of these segments benefits from POC solutions, which offer quick diagnostic results that facilitate immediate medical decision-making and patient management. For example, POC diagnostics for respiratory diseases allow for faster diagnosis of infections like influenza and COVID-19, helping to prevent transmission and support effective triage in healthcare facilities. Similarly, POC diagnostics for hospital-associated infections aid in controlling infections within healthcare settings, reducing morbidity and healthcare costs. These varied applications collectively highlight the market's potential to improve access to healthcare, streamline diagnostics, and support better health outcomes across diverse infectious disease challenges.

Global Point-of-Care (POC) Infectious Disease Diagnostics Market, Segmentation by End User

The Global Point-of-Care (POC) Infectious Disease Diagnostics Market has been segmented by End User into Hospitals, Home-Care Settings, Diagnostic Laboratories and Others.

The global point-of-care (POC) infectious disease diagnostics market is segmented by end user, with a primary focus on hospitals, which constitute a significant share due to the high volume of patients and extensive diagnostic needs. Hospitals utilize POC diagnostics to promptly detect infections, enabling rapid treatment decisions that are crucial in controlling the spread of infectious diseases. This segment benefits from the strong infrastructure and availability of trained personnel in hospitals, which enhances the efficiency and reliability of diagnostic procedures. The demand for POC diagnostics in hospitals is driven by the need to reduce hospital stays, manage costs, and improve patient outcomes through timely diagnosis and intervention.

Another important end-user segment in the POC infectious disease diagnostics market is home-care settings, which are growing in importance as healthcare trends shift toward patient-centered care and self-management. In home-care settings, POC diagnostics allow patients to monitor infections in real time, especially those with chronic health conditions or compromised immunity. The ease of use, portability, and accuracy of modern POC devices make them suitable for home-care applications, empowering patients to take control of their health. Additionally, the COVID-19 pandemic has amplified the need for POC diagnostics in home-care settings, as many patients now prefer avoiding hospital visits when possible.

Diagnostic laboratories also play a vital role in the POC infectious disease diagnostics market by serving as key facilities for analyzing and confirming infectious disease cases. Although these laboratories traditionally focus on centralized testing, there is an increasing integration of POC diagnostics to complement existing processes. This approach is especially useful in rural and remote areas where full-scale laboratory services may not be readily accessible. By offering POC diagnostics, laboratories can ensure quicker access to results and support clinicians in diagnosing infections more efficiently. The "others" category, which includes clinics, research institutes, and specialty centers, further diversifies the market by extending POC diagnostic capabilities to various healthcare settings, each tailored to meet specific needs in infectious disease management.

Global Point-of-Care (POC) Infectious Disease Diagnostics Market, Segmentation by Geography

In this report, the Global Point-of-Care (POC) Infectious Disease Diagnostics Market has been segmented by Geography into five regions; North America, Europe, Asia Pacific, Middle East and Africa and Latin America.

Global Point-of-Care (POC) Infectious Disease Diagnostics Market Share (%), by Geographical Region, 2024

North America led the global infectious disease point-of-care (POC) diagnostics market with a share of 35.92% in 2022. This dominance can be attributed to the growing adoption of advanced POC diagnostics for detecting various infectious diseases. Additionally, the region has witnessed an increase in strategic partnerships between governmental organizations and industry players, which has further fueled the development and adoption of rapid diagnostic tests. For example, in February 2021, Thermo Fisher Scientific Inc. acquired Mesa Biotech, Inc. to expand its POC molecular diagnostic portfolio, incorporating the Accula System—a user-friendly, POC PCR-based platform for infectious disease testing.

Europe secured the second-largest market share and is projected to experience significant growth at a notable CAGR during the forecast period. This growth is driven by an increase in strategic collaborations among key market players. In February 2023, BIOSYNEX SA announced its acquisition of Chembio Diagnostics, Inc., aimed at strengthening its POC testing portfolio. Similarly, in December 2021, F. Hoffmann-La Roche Ltd acquired TIB Molbiol Group to enhance its ability to rapidly develop assays for infectious diseases.

The Asia Pacific market is expected to exhibit the highest CAGR, driven by the growing presence of market players and increased adoption of POC diagnostic kits. Significant investments from regional market players are expected to further boost demand for advanced diagnostic products. For instance, in June 2022, Cipla Limited signed an agreement to acquire a partial stake in Achira Labs Private Limited. This acquisition focused on developing and commercializing POC medical test kits in India, where Achira Labs specializes in molecular assays and immunoassays for infectious diseases.

In contrast, the markets in Latin America and the Middle East & Africa hold smaller shares, primarily due to a lack of awareness within the healthcare community regarding the benefits of point-of-care diagnostics. However, as awareness grows and access to advanced diagnostic solutions improves, these regions are expected to gradually see increased adoption of POC diagnostics.

This report provides an in depth analysis of various factors that impact the dynamics of Global Point-of-Care (POC) Infectious Disease Diagnostics Market. These factors include; Market Drivers, Restraints and Opportunities Analysis.

Market Drivers, Restraints and Opportunities Analysis.

Drivers:

• Technology advancements
• Increasing demand for rapid testing
• Growing prevalence of infectious diseases

• Focus on decentralized healthcare delivery-The Global Point-of-Care (POC) Infectious Disease Diagnostics Market is the growing focus on decentralized healthcare delivery. Decentralized healthcare aims to make diagnostic and treatment services accessible at or near the point of need rather than relying solely on centralized hospital or laboratory settings. This shift is especially beneficial in infectious disease diagnostics, where rapid identification and treatment are crucial to controlling the spread of diseases. POC diagnostic tools, including portable and user-friendly devices, enable quick testing in community health centers, clinics, and even remote locations, improving healthcare accessibility and outcomes.

  The emphasis on decentralized healthcare is largely driven by the need to reach underserved and rural populations, especially in low- and middle-income countries where infrastructure and resources are limited. In these regions, centralized labs may be distant or difficult to access, making POC diagnostics essential for early disease detection and containment. For instance, rapid tests for diseases like HIV, tuberculosis, and malaria can be administered by local health workers, enabling immediate diagnosis and timely treatment without the need for patients to travel long distances. Decentralized healthcare helps reduce diagnostic delays, enhances disease monitoring, and allows health interventions to be more effectively deployed.

  Decentralizing healthcare delivery also strengthens healthcare systems in times of public health crises, such as pandemics. The ability to deploy POC infectious disease diagnostics in a widespread manner allows for faster response and containment, reducing the strain on centralized hospitals and laboratories. As global health priorities increasingly focus on disease prevention and management within communities, the adoption of POC diagnostics is likely to expand further, fueled by technological advancements that make these devices more accurate, affordable, and accessible.

Restraints:

• Regulatory challenges
• Limited reimbursement policies
• High initial setup costs

• Concerns about test accuracy- Concerns about test accuracy are significant restraints in the Global Pediatric Ultrasound Market, as accuracy is critical when diagnosing and treating pediatric patients. Ultrasound imaging, while non-invasive and relatively safe, can sometimes produce results that are less precise than other imaging modalities like MRI or CT scans. For pediatric patients, whose smaller anatomy and unique physiological characteristics require highly accurate readings, even minor inaccuracies can lead to misdiagnosis or inappropriate treatment. In turn, these concerns can make healthcare providers cautious about relying solely on ultrasound for pediatric assessments, particularly in critical or complex cases.

  These accuracy concerns are further complicated by the variability in operator skills. Unlike automated imaging systems, ultrasound technology requires a trained technician or radiologist to capture and interpret the images correctly. For pediatric ultrasound, this becomes even more challenging, as children may not always cooperate fully during scans, making it difficult to get clear images. Operator error or variability in skill levels can thus contribute to inconsistencies in results. As a result, some healthcare facilities may hesitate to invest in ultrasound technology as a primary diagnostic tool for pediatric care, opting instead for more reliable, albeit more costly, imaging solutions when accuracy is paramount.

  Advancements in ultrasound technology, though rapid, have yet to fully resolve all accuracy-related issues, particularly in handheld devices that are popular in pediatric care for their portability. While manufacturers are continuously improving image resolution and diagnostic capabilities, handheld devices often lack the same level of detail and diagnostic scope as their larger, cart-based counterparts. Consequently, the adoption of pediatric ultrasound in some regions may be limited by these unresolved concerns, as providers wait for further advancements that could improve both accessibility and precision. As technology evolves, addressing accuracy limitations will be crucial in driving widespread acceptance and reliance on ultrasound as a standard tool in pediatric diagnostics.

Opportunities:

• Emerging markets expansion
• Development of portable diagnostic devices
• Integration of AI in diagnostics

• Rising investment in healthcare infrastructure-Rising investment in healthcare infrastructure is a crucial factor driving advancements across global healthcare systems. Governments and private entities are increasing their spending on healthcare facilities, equipment, and technology, particularly in emerging economies where access to quality healthcare services is still developing. This investment boosts the capacity of hospitals, clinics, and diagnostic centers to serve larger populations with more sophisticated medical care. As a result, healthcare providers can accommodate rising patient volumes and deliver improved standards of care, which is crucial in meeting the growing demand for health services globally.

  Investment in healthcare infrastructure facilitates the adoption of advanced medical technologies, such as digital imaging systems, telemedicine, and AI-driven diagnostic tools. With these resources, healthcare facilities can enhance diagnosis, treatment, and monitoring of patients across a wide array of medical specialties. For instance, in pediatric care, upgraded ultrasound machines and diagnostic tools allow clinicians to deliver timely, accurate assessments, improving patient outcomes significantly. These technologies also enable healthcare systems to streamline workflows, reduce wait times, and increase operational efficiency, ultimately benefiting both patients and healthcare providers.

  In addition to improving patient care, investments in healthcare infrastructure play a vital role in economic growth and job creation. By expanding and upgrading healthcare facilities, governments and private investors create employment opportunities for medical professionals, technicians, and support staff, contributing to a more robust healthcare workforce. Furthermore, enhanced healthcare infrastructure makes countries more resilient to health crises, as seen during the COVID-19 pandemic, where well-equipped hospitals and testing centers were pivotal in managing patient care. In the long term, such investments not only improve health outcomes but also contribute to sustainable development and better quality of life for populations worldwide.

Key players in Global Point-of-Care (POC) Infectious Disease Diagnostics Market include:

• Abbott Laboratories
• AccuBioTech
• Becton, Dickinson and Company
• Chembio Diagnostic Systems
• Danaher Corporation
• EKF Diagnostics
• Instrumentation Laboratory Company
• Johnson & Johnson
• Nova Biomedical
• PTS Diagnostics
• Quidel Corporation
• Roche Diagnostics
• Sekisui Diagnostics
• Siemens Healthineers
• Trinity Biotech

In this report, the profile of each market player provides following information:

• Company Overview and Product Portfolio
• Key Developments
• Financial Overview
• Strategies
• Company SWOT Analysis